硫酸黏菌素与头孢他啶-阿维巴坦治疗碳青霉烯耐药的肠杆菌及铜绿假单胞菌感染的疗效比较

Comparison of effect between colistin sulfate and ceftazidime-avibactam for treating
infections caused by carbapenem-resistant Enterobacteriaceae (CRE) andPseudomonas aeruginosa (CRPA)

  • 摘要:
    背景 耐碳青霉烯肠杆菌(carbapenem-resistant Enterobacteriaceae,CRE)及耐碳青霉烯铜绿假单胞菌(carbapenem resistant Pseudomonas aeruginosa,CRPA)感染近年来在我国广泛传播,为临床工作带来了极大的挑战。硫酸黏菌素及头孢他啶-阿维巴坦被认为是治疗CRE及CRPA的最后手段。目的 比较硫酸黏菌素与头孢他啶-阿维巴坦治疗CRE及CRPA感染的疗效。方法 收集应用硫酸黏菌素或者头孢他啶-阿维巴坦治疗CRE或CRPA感染患者的基线数据,以及抗感染治疗后的结局指标和不良反应发生情况。结果 本研究共纳入82例患者,其中硫酸黏菌素组42例,中位年龄83(62.8 ~ 91.0)岁,男性31例;头孢他啶-阿维巴坦组40例,中位年龄80.5(56.5 ~ 91.8)岁,男性29例。硫酸黏菌素组与头孢他啶-阿维巴坦组的基线数据之间没有统计学差异。在结局指标方面,硫酸黏菌素组的临床治愈率及7天生存率与头孢他啶-阿维巴坦组相比,分别为(50% vs 40%,P>0.05)和(71.4% vs 62.5%,P>0.05)。在不良反应方面,两组肾损伤的发生率亦没有明显统计学差异。结论 硫酸黏菌素治疗CRE或CRPA感染的效果与头孢他啶-阿维巴坦相仿。在临床应用中,可以根据药物的可及性,选择具体的药物来进行抗感染治疗。

     

    Abstract:
    Background Carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) infections have been widely spreading in our country in recent years, posing a great challenge to clinical work. Colistin sulfate and ceftazidime-avibactam are the last resort for treating CRE and CRPA. Objective To compare the effect of colistin sulfate and ceftazidime-avibactam for treating CRE and CRPA infections.Methods Basic information of patients with CRE or CRPA infections treated with colistin sulfate or ceftazidime-avibactam and outcomes after anti-infective treatment were collected, respectively.Results A total of 82 patients were included in this study, with 42 cases in the colistin sulfate group and 40 cases in the ceftazidime-avibactam group. The median age in the colistin sulfate group was 83.0 (62.8-91.0) years, and 31 cases were male. In the ceftazidime-avibactam group, the median age was 80.5 (56.5-91.8) years, and there were 29 males. There was no statistical difference in the basic information between the colistin sulfate group and the ceftazidime-avibactam group. Regarding outcomes, compared with the ceftazidime-avibactam group, the clinical cure rate and 7-day survival rate in the colistin sulfate group were 50% vs 40%, and 71.4% vs 62.5%, without significant difference (P>0.05, respectively). Concerning adverse effects, no statistically significant difference was observed in the incidence of renal injury between the two groups. Conclusion The effectiveness of colistin sulfate in treating CRE or CRPA infections is similar to ceftazidime-avibactam, with no significant differences. In clinical practice, specific drugs can be selected for anti-infective treatment based on drug availability.

     

/

返回文章
返回